Key result
Enoxaparin dosing remains uncertain in obese patients and its role in COVID-19 coagulopathy requires investigation.
Why the study?
Enoxaparin is indicated for thrombotic conditions, but dosing uncertainty remains in obese patients and its role in COVID-19-associated coagulopathy has prompted investigation.
Enoxaparin is a widely used low-molecular weight heparin for thrombotic conditions, though dosing in obese patients remains uncertain and its role in COVID-19 coagulopathy is under investigation.
Uncertainties in obese dosing and COVID-19 use warrant caution; leaves open dedicated pharmacokinetic and outcome trials.
The development of low-molecular and ultra-low-molecular weight heparins has changed anticoagulation treatment options. Enoxaparin is a low-molecular weight heparin (LMWH), which works on Factor Xa and is indicated for both the prevention and treatment of various thrombotic conditions. Dosing is individualised to patient and condition. There is uncertainty about the dose in obese patients, with no clear consensus on an appropriate dose. COVID-19-associated coagulopathy has resulted in the investigation of enoxaparin to help reduce mortality.
No takes yet. Share an insight, caveat, or question.
Padayachee et al. (2021) conducted a review in Thrombotic conditions and COVID-19-associated coagulopathy. Enoxaparin was evaluated. Enoxaparin is a low-molecular weight heparin indicated for thrombotic conditions, though dosing in obese patients remains uncertain and its role in COVID-19 coagulopathy is under investigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: